What the trial was testing
The trial enrolled 453 patients with epilepsy. The study was sponsored by Children's Hospital Medical Center, Cincinnati and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Ethosuximide kept 53% of children seizure-free at 16 weeks vs. 29% for lamotrigine.
New England Journal of Medicine · 2010 · NCT00088452
These findings — that of children seizure-free at 16 weeks on ethosuximide compared with lamotrigine — were published in the New England Journal of Medicine and represent the headline result of the study.
Researchers tracked outcomes across 453 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with epilepsy, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Ethosuximide is FDA-approved and widely available as a first-line option for childhood absence epilepsy. This study established it as the preferred starting drug because it controlled seizures as well as valproic acid but caused fewer attention side effects. Ask a pediatric neurologist which medication fits your child's situation.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open epilepsy trials
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)
The goal of this pragmatic, decentralized, pre-consented, event-driven, randomized controlled trial is to investigate the efficacy of add-on ketamine to second-dose midazolam for prehospital treatment of epileptic children with convulsive status epilepticus.